CION Ameerpet
A glioblastoma diagnosis is frightening. This page explains what GBM is, its symptoms and causes, and how it is treated. CION's neuro-oncology team plans every step with you.
Glioblastoma — also written GBM or glioblastoma multiforme — is the most common and most aggressive malignant primary brain tumour in adults. It is a WHO Grade 4 glioma, which means it grows quickly and sends tiny threads of tumour into the healthy brain around it. GBM begins in the brain's glial support cells, and it is most common after the age of 60, though younger adults can develop it too.
Because glioblastoma is genuinely malignant, it is one of the brain tumours we correctly call brain cancer. That is different from many other brain growths — most meningiomas, for example, are benign and are not cancer. This page sits within our wider brain cancer & tumour hub and explains GBM in plain language: what it is, the symptoms, the causes, the molecular tests that change the plan, and how it is treated.
Glioblastoma is graded by the World Health Organization as a Grade 4 glioma — it is not "staged" with the Stage I–IV (TNM) system used for most cancers, because GBM almost never spreads outside the brain. Since the 2021 WHO classification of brain tumours, the diagnosis also depends on molecular markers such as IDH status — so two tumours that look identical under the microscope can be classified, and treated, differently.
Not all brain tumours behave the same way. Understanding what sets GBM apart helps explain why treatment is urgent and why a coordinated team matters so much.
As a Grade 4 tumour, glioblastoma grows rapidly — often over weeks rather than months. This is why new symptoms tend to appear and worsen quickly, and why an urgent MRI is arranged when GBM is suspected. Faster diagnosis gives more treatment options.
GBM does not sit as a neat ball. It sends microscopic fingers of tumour into surrounding healthy brain, which is why it cannot usually be removed completely by surgery alone — and why radiation and chemotherapy follow to target the cells left behind.
Two glioblastomas can look identical under the microscope yet behave very differently. IDH status and MGMT methylation from the biopsy tell us how the tumour is likely to respond — so testing is as important as the surgery itself.
GBM care is among the most complex in oncology. Surgery, radiation oncology and medical oncology must work together from day one. At CION, every glioblastoma case goes to a multidisciplinary tumour board before any plan is finalised.
The symptoms of glioblastoma depend on where in the brain the tumour grows, because different areas control different functions. Because GBM grows quickly, symptoms usually develop over a few weeks. Importantly, none of these symptoms means a tumour on its own — most headaches, and many seizures, have other causes. What matters is a symptom that is new, persistent and progressive.
Red flag: a first adult seizure, or new one-sided weakness, speech loss or sudden vision change that is persistent and progressive, always warrants an urgent brain MRI. Speak to a CION neuro-oncologist if you or a loved one has these signs.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Whether you want to understand your MRI, confirm molecular testing has been done, or get a second opinion before treatment — CION's neuro-oncology team is here to help, with same-week appointments.
In most patients, the cause of glioblastoma is unknown. GBM is not something you caused, it is not contagious, and in the large majority of cases it is not inherited. The few established factors are:
Because the causes are largely unknown, there is no reliable way to prevent or screen for GBM in the general population. What matters most is recognising warning symptoms early and getting prompt imaging.
Diagnosing glioblastoma takes more than a single scan. The pathway confirms the tumour, identifies its exact type, and — crucially — reads its molecular biology so the right treatment can be chosen.
An MRI with contrast is the gold standard for finding and characterising a glioblastoma. It shows the tumour's location, size, and its relationship to critical brain areas, and reveals features that suggest an aggressive, high-grade tumour. Specialised sequences add information about blood flow and the tumour's closeness to speech and movement areas.
Imaging can strongly suggest GBM, but only a tissue sample confirms it. Tissue is obtained either during surgical removal of the tumour or, for deep or risky locations, via a stereotactic needle biopsy. Both the biopsy and any neurosurgery are coordinated with accredited neurosurgical partners; CION manages the diagnosis, molecular testing and the treatment that follows.
This is where glioblastoma care has changed most. Two markers from the tumour tissue guide everything that follows. IDH status separates true (IDH wild-type) glioblastoma from IDH-mutant tumours, which behave differently and have a better outlook. MGMT promoter methylation predicts how well alkylating chemotherapy is likely to work — methylated tumours respond better and are associated with longer survival. The 2021 WHO classification is built around these markers (per NCCN and EANO guidance), which is why grade alone no longer tells the full story. CION arranges IDH and MGMT testing as standard on every malignant glioma sample.
According to published ranges from NCCN and EANO, glioblastoma has no single survival figure — outcomes depend on age, fitness, how much tumour can be safely removed, and molecular markers. Patients whose tumours show MGMT methylation tend to respond better to alkylating chemotherapy and live longer on average than those without it. This is exactly why molecular testing should be part of the standard work-up for every glioblastoma — if it has not been arranged, ask for it before treatment begins.
The internationally established standard for glioblastoma is the Stupp protocol, named after the trial that defined it. It combines three phases, and CION coordinates them as one continuous plan. For the full detail, see our dedicated page on how glioblastoma is treated.
After treatment, regular MRI scans monitor for any change. The first scan after chemoradiation can be tricky to read — a phenomenon called pseudoprogression can make the scan look worse than the tumour really is, due to post-treatment inflammation. Experienced neuro-oncologists recognise this and avoid changing the plan prematurely.
What CION delivers directly: radiation therapy (IMRT/IGRT), systemic drug therapy, imaging and diagnosis, molecular testing, steroid and seizure management, and supportive and rehabilitation care. Specialist radiosurgery and neurosurgery are arranged through coordinated, accredited partners.
A glioblastoma diagnosis moves quickly, and it is normal to feel overwhelmed. You deserve time to understand what is happening and to feel confident in the plan. At CION, every case is reviewed by a tumour board — surgery, radiation and medical oncology deciding together — and we make decisions for healing, not billing, with transparent costs explained up front.
A second opinion is particularly worthwhile in three situations:
To go deeper, read about how glioblastoma is treated (surgery, radiation, chemotherapy) and glioblastoma survival & prognosis. You can also explore our broader brain tumor treatment in Hyderabad page, or meet the best brain cancer doctors in Hyderabad.
Ready to talk it through? Book a free consultation or call 18002028726 — we'll walk this journey with you.
Get a free written second opinion from CION's neuro-oncology tumour board — especially valuable before treatment begins, or if IDH and MGMT molecular testing hasn't yet been arranged.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Glioblastoma — also called GBM or glioblastoma multiforme — is the most common and most aggressive malignant primary brain tumour in adults. It is a Grade 4 glioma, meaning it grows quickly and spreads tiny fingers of tumour into nearby healthy brain. GBM arises from the glial support cells of the brain and is most common after the age of 60, though it can occur at any age. Because it grows rapidly, symptoms often appear over weeks rather than months. Despite being the most feared brain-tumour diagnosis, modern treatment — surgery, radiation and chemotherapy together — has meaningfully improved outcomes, and care is far better when planned by an experienced neuro-oncology team.
Glioblastoma is one specific type of brain cancer — the most aggressive primary brain cancer. "Brain cancer" is a broad term covering all malignant brain tumours, while "brain tumour" includes both benign and malignant growths. GBM is genuinely malignant, so calling it brain cancer is accurate. However, many other brain tumours (such as most meningiomas) are benign and are not cancer. This is why the exact diagnosis from a biopsy and molecular testing matters so much — it tells you whether a tumour is GBM, a lower-grade glioma, or something benign, and each has a very different treatment plan and outlook.
In most patients, the cause of glioblastoma is unknown. GBM is not caused by anything the patient did, and it is not contagious or inherited in the vast majority of cases. The only firmly established environmental risk factor is previous high-dose radiation to the head, which can rarely lead to a tumour years later. A small number of cases occur in people with rare inherited conditions such as Li-Fraumeni syndrome or neurofibromatosis. Large studies have not found a clear link between mobile-phone use and glioblastoma. Age is the strongest pattern — GBM becomes more common after 60.
The standard treatment is the Stupp protocol: maximum safe surgical removal of the tumour (coordinated with accredited neurosurgical partners), followed by six weeks of daily radiation given together with daily oral alkylating chemotherapy, then several monthly cycles of the same chemotherapy. Molecular testing of the tumour tissue — IDH status and MGMT methylation — guides how well chemotherapy is likely to work and shapes the plan. CION delivers the radiation, systemic (drug) therapy, imaging, molecular testing, steroid and seizure management, and supportive care directly, and coordinates the neurosurgery with accredited neurosurgical partners. You can read more on our how glioblastoma is treated page.
There is no single survival figure — outcomes depend on age, general fitness, how much tumour can be safely removed, and molecular markers. Published ranges from NCCN and EANO describe a median overall survival of roughly 15 to 18 months with full standard treatment, and a meaningful minority of patients live longer. Patients whose tumours show MGMT methylation tend to respond better to chemotherapy and live longer on average than those without it. These figures are ranges from large studies, not promises for any one person. Our glioblastoma survival & prognosis page explains what shifts the outlook.
Because GBM grows quickly, symptoms usually develop over a few weeks. The most common early signs are new, persistent and worsening headaches (often worse in the morning or waking the person from sleep), a first-ever seizure in an adult, one-sided weakness or numbness, sudden difficulty with speech or finding words, vision changes, and noticeable changes in memory, behaviour or personality. None of these symptoms means a tumour on its own — most headaches and many seizures have other causes. But a new symptom that is persistent and progressive, especially a first adult seizure or one-sided weakness, should always prompt an urgent brain MRI.
Molecular testing on the tumour tissue is now as important as the surgery itself. Two markers matter most. IDH status separates true (IDH wild-type) glioblastoma from IDH-mutant tumours, which behave differently and have a better outlook. MGMT promoter methylation predicts how well alkylating chemotherapy will work — methylated tumours respond better and are associated with longer survival. The 2021 WHO classification of brain tumours is built around these markers, which is why grade alone no longer tells the full story. At CION, IDH and MGMT testing is arranged as standard on every malignant glioma sample so the treatment plan fits your exact tumour biology.
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.